Publication Date: 25 Apr 2013
Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 17-34
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
PDF (700.86 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
In my opinion the review process in all the Libertas Academica journals I have had the privilege of reviewing papers for is second to none. The entire process is a click away and all the editorial staff are very cooperative. The papers that are submitted are of top quality and I am sure the journals will gain the status of high impact journals in a very short time.